1 / 32

Amyloidosis: Choices In the use of Conventional & High Dose Therapy

Scottsdale, Arizona. Rochester, Minnesota. Jacksonville, Florida. Amyloidosis: Choices In the use of Conventional & High Dose Therapy. Stem cell transplant for AL. Why does stem cell transplant work ? Is it better treatment or Do we just select the best patients to offer transplant ?. 100.

felice
Télécharger la présentation

Amyloidosis: Choices In the use of Conventional & High Dose Therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Amyloidosis: Choices In the use of Conventional & High Dose Therapy

  2. Stem cell transplant for AL Why does stem cell transplant work ? Is it better treatment or Do we just select the best patients to offer transplant ?

  3. 100 90 80 70 60 Percent alive 50 40 PBSCT Cases (N=63)Controls (N=63) 30 20 P < 0.001 10 0 Years follow-up 0 1 2 3 4 PBSCT for AL Case Control: OS from Diagnosis Dispenzieri, et al, Blood, 2004. 103(10): p. 3960-3

  4. Transplantation Organ response Organ responses take timeMedian 5-6 mo Day 100, hematologic CR Complete organ response Year 0 1 2 3 4

  5. Averaged change in proteinuria after stem cell transplantation. Differences in proteinuria became and remained significant after 3 months.

  6. Response to SCT

  7. Treatment-related mortality in PBSCT (any death occurring before day 100 post transplant) • Cox multivariate analysis: • Number of organs involved • Serum creatinine • Gertz BMT 2004

  8. Experience Matters: CIMBTR results by year of transplantation

  9. Prognostic Factors for SCT for AL • Number of organs clinically involved • Cardiac chemistries • Troponins • BNP • FLC assay • Absolute level • Response to Tx • Serum albumin and alkaline phosphatase

  10. High dose 83 12% 22% 13% 37% 72% Total Lo dose 42 19% 21% 2% 24% 48% Grand Total 125 14% 22% 10% 33% 64% AL Amyloid Responses after PBSCT Gertz et al BMT, 2004 Conditioning N Death <d+100 Heme only Organ only Both Any

  11. 1 .8 .6 P=0.05 %, Surviving .4 High Intensity .2 Intermediate Intensity 0 0 10 20 30 40 50 60 70 80 Months Amyloid Transplant Survival Dose Intensity Gertz et al BMT, 2004

  12. Myeloma causes of Death relate to Tumor Mass In AL death is driven by organ Failure/dysfunction If the M protein falls does this translate to improved survival ? How much of a reduction is sufficient to impact outcomes ? Should M protein be used as a trial endpoint? Does Tumor Mass Reduction Matter: Why does transplant work ?

  13. AL TRANSPLANT POPULATION • Median 24-hour urine protein loss was 3.4 g/day • One-, 2-, and 3-organ involvement occurred in 48%, 38%, and 14% of patients, respectively • D+100 mortality 11% • CR IF- S&U & NL FLC ratio • PR 50% S&U M component & involved FLC

  14. AL TRANSPLANT POPULATION • 69% of patients had renal involvement, 51% had cardiac involvement, 11% had peripheral nerve involvement, and 16% had hepatic involvement. • Echocardiographic analysis showed a median septal thickness of 12 mm and a median ejection fraction of 65%. • Median % of bone marrow plasma cells was 7, range from 1 - 78

  15. Overall Survival of 282 Transplanted Amyloid Patients Stratified by Hematologic Response CR (n=93) PR (n=108) Surviving NR (n=81) Months CP1245979-1

  16. INTERPRETING AL RESPONSE/SURVIVAL • Skew in the data since with an 11 % mortality rate a substantial number of patients become inevaluable for response • Landmark analysis at 6 months to exclude early deaths from advanced organ failure gives a better assessment of responses impact on outcome

  17. Landmark Analysis of Amyloidosis Patients that Survived 6 Months Stratified Based onHematologic Response CR (n=86) PR (n=91) Surviving NR (n=36) P=0.001 Months CP1245979-2

  18. Response Translates to Survival • Do patients with echocardiographic evidence of Cardiac AL also benefit from transplant? • Recognizing that patients with cardiac AL are a highly selected group (milder)…

  19. Overall Survival of 151 TransplantedCardiac Amyloid Patients Stratified byHematologic Response CR n=42 n=56 Surviving NR n=53 P<0.001 Months CP1245979-3

  20. Landmark Analysis of Cardiac AmyloidPts that Survived 6 Months Stratified Basedon Hematologic Response n=38 n=39 Surviving n=18 P<0.001 Months CP1245979-4

  21. DETERMINANTS OF RESPONSE • There was a difference in response rate based on conditioning intensity (p<0.01) and age (p=0.046). However, since this was not a prospective study, patients who received higher intensity therapy tended to be younger and have less extensive organ involvement particularly cardiac

  22. What this study does tell us • In Amyloidosis response is an appropriate surrogate for survival • Response is a legitimate endpoint for Clinical Studies of Therapy including cardiac AL • Complete Responders live longer than partial responders • Partial responders live longer than non responders even correcting for early death by landmark

  23. What this study does not tell us • Is Transplant any better than Chemotherapy ± Novel Agents? • What role does patient selection have in determining response? • Should patients who fail to achieve CR receive post transplant consolidation to move them to CR

  24. Autologous SCT Versus Oral M-DEX for AL • 100 patients randomized to Auto SCT with MEL 140 or 200 mg/m2 or oral M-DEX • No difference between the 2 arms for hematologic responses (65 & 64%). • Median survival is 56.9 months M-Dex arm & 48.6 months for the ASCT arm (p=0.2) • TRM 24%(SCT) vs 2% (M-DEX) • In the ASCT arm only 37 pts (74%) received the planned treatment Jaccard , ASH 2005

  25. Introduction Conventional Dose Therapy • Majority of patients not eligible for PBSCT • Age • Organ dysfunction • Outcomes with conventional treatment poor • Treatments for amyloid evolve from myeloma therapy

  26. Mel - Dex • First therapy to show significant improvement over MP • Phase II multicenter trial by Italian Amyloidosis Center in patients not eligible for SCT Melphalan (0.22 mg/kg) Dexamethasone (40 mg) Given po on days 1- 4 q 28 days Palladini, et al., Blood 103(8): 2004.

  27. Mel - Dex • Total of 46 pts. treated • Hematologic Response Rate 67% (33% CR) • Organ response in 48% • 2 treatment-related deaths in first 100 days • Median Survival = 5.1 yrs.

  28. IMiDs for AL Amyloidosis

  29. ConclusionsLenalidomide + Dex for AL • Activity • Heme responses in ~ 60% • Organ responses in ~ 30% • Most common toxicities are hematologic; next is rash & fatigue • Pre-treatment cardiac biomarkers predict for trial retention, PFS & OS

  30. Bortezomib for AL • No prospective trials • UK experience in relapsed AL: • 18 pts. (9 had Dex added) • Median # prior therapies = 3 • Heme response in 14 (77%), CR 3 (16%) • Organ response in 5 (27%) • Est. median survival = 22 mos. Wechalekar, et al., Blood 108: 129a, 2006

  31. Mayo Randomized Trial Randomization SCT with MEL 200 mg/m2 Mel 20 mg/m2 q 6 weeks + dex 40 mg x 4 days every 3 weeks X 10 cycles

  32. Not wanting transplant Mel 200 HSCT Mel-Dex Hematologic Response No Hematologic Response More chemotherapy Observation Observation Newly Diagnosed AL Amyloidosis Low risk 1-2 organs Age < 71 High Risk Severe cardiac, Or not ‘low risk’

More Related